Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525468 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects
A Phase 1 study, sponsored by Technoderma Medicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT05525468 is a Phase 1 study that has completed, run by Technoderma Medicines. The registered enrollment target is 58 participants.
The verdict
NCT05525468, a Phase 1 study, has completed, sponsored by Technoderma Medicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, dose escalation study of TDM-180935 following topical administration in healthy male subjects, 18 to 55 years old
Interventions
- DRUG Placebo
- DRUG TDM-180935
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2023-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05525468
The ClinicalTrials.gov registry entry for NCT05525468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Technoderma Medicines, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05525468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05525468 about?
NCT05525468 is a clinical study titled "A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects". Multi-center, randomized, double-blind, vehicle-controlled, parallel group, dose escalation study of TDM-180935 following topical administration in healthy male subjects, 18 to 55 years old
What is the current status of trial NCT05525468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2023-02-08. Estimated completion is 2023-10-13.
What interventions are being tested in trial NCT05525468?
The interventions under investigation include: Placebo (DRUG), TDM-180935 (DRUG).
Who is sponsoring clinical trial NCT05525468?
This trial is sponsored by Technoderma Medicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.